Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 11/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16940692 | 0.82 | KMT2A (0.44) | CYP2D6CYP2C9NOTUMBRD4POLB | |
| SCHEMBL1106902 | 0.81 | CYP2D6 (0.39) | CYP2D6CYP2C9POLBGPBAR1 | |
| SCHEMBL30379462 | 0.79 | TSHR (0.44) | CYP2D6CYP2C9NOTUMBRD4POLB | |
| SCHEMBL30379815 | 0.79 | GAA (0.49) | — | |
| SCHEMBL26088235 | 0.79 | GAA (0.49) | — | |
| SCHEMBL24597094 | 0.79 | KDM1A (0.52) | CYP2D6CYP2C9GPBAR1 | |
| SCHEMBL26092624 | 0.77 | GAA (0.48) | — | |
| SCHEMBL30910084 | 0.77 | GAA (0.48) | — | |
| SCHEMBL9607910 | 0.77 | NOTUM (0.58) | CYP2D6CYP2C9NOTUMBRD4POLB | |
| SCHEMBL30910069 | 0.76 | ALDH1A1 (0.52) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP2D6 4717/4885CYP2C9 4870/4885NOTUM 2328/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | CYP2D6 4649/4885CYP2C9 4863/4885NOTUM 2585/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP2D6 4717/4885CYP2C9 4870/4885NOTUM 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.